Evolent Health (EVH) PT Lowered to $10 at Truist Securities

Truist Securities analyst Jailendra Singh lowered the price target on Evolent Health (NYSE: EVH) to $10.00 (from $16.00) while maintaining a Buy rating.

The analyst comments "We had a post-quarterly call with EVH management to discuss 3Q25 results, its Q4 guide, thoughts on 2026, cost trends, among other topics. In the text below, we list our questions and the company’s responses. The answers are not verbatim, but we put the company’s answers in their proper context in a give and take format."

You May Also Be Interested In

• Palantir (PLTR) PT Raised to $250 at DA Davidson
• Descartes (DSGX) PT Raised to $98 at Scotiabank
• Jefferies on SolarEdge (SEDG): 'The Turnaround Looks to be Over'